Studio discussion: managing cardiovascular risk factors in primary care, including type 2 diabetes, hypertension, and hyperlipidaemia

The Government’s 10-year plan for the NHS (‘Fit for the future’) has a dedicated section on prevention, including a ‘moonshot’ to end the obesity epidemic. But what is the role of GP in the prevention of cardiovascular disease (CVD)?In this episode of the Clinical Update podcast, the MIMS Learning editors explore NICE recommendations for combination therapy to help patients achieve lipid targets for secondary prevention, the promotion of SGLT2 inhibitors to first-line options for both heart failure and type 2 diabetes, and the differences between UK and international guidelines on hypertension. Additionally, given obesity is a huge risk factor for CVD, the editors review how the management of obesity must encompass more than just GLP-1 medications.Educational objectivesAfter listening to this podcast, healthcare professionals should be better able to: Outline the prevention steps proposed in the NHS 10-year planDiscuss additional therapeutic options for achieving lipid targetsReview revised recommendations for heart failure and type 2 diabetesUnderstand the differences between UK and international hypertension targetsYou can access the website version of this podcast, along with a list of key learning points, on MIMS Learning - and make notes for your appraisal. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser.Please note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.MIMS LearningSubscribe to MIMS LearningGuidance update: latest NICE guidelines on cardiovascular disease risk assessment and reductionGuidance update: NICE guidelines on hypertensionObesity in adultsPodcast: Dr Toni Hazell on weight loss injections and women’s healthPodcast: stress and its effect on the heartMIMSNICE confirms first-line role of SGLT2 inhibitors in final heart failure guidanceMonitoring requirements for hyperlipidaemia treatments Hosted on Acast. See acast.com/privacy for more information.

There are no comments yet.

Please log in to write the first comment.